BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers with clear genetic drivers. Its pipeline includes Acoramidis (AG10) for amyloidosis TTR (ATTR), low-dose infigratinib for achondroplasia, Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418 for LGMD2I (LGMDR9). The company's programs range from early science to advanced clinical trials, aiming to discover, create, test, and deliver these treatments to patients. The BBIO average annual return since 2019 is shown above.
The Average Annual Return on the BBIO average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BBIO average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free BBIO Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
